Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 6Sarcoma 3Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Whole-Brain Radiotherapy 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Locally Advanced Thyroid Gland Carcinoma 1Leiomyosarcoma 1Kidney Neoplasms 1Hyperthermia 1HER2-Negative Breast Cancer 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Thyroid Cancer Patients Who Received Target Therapy × anlotinib × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡